The dose on the label, and the dose in the vial

Most of the writing here is about whether a molecule does what it's said to do: what a trial found, what a mechanism suggests, what's still unknown. That's one question. There's a second one that gets far less attention, and it sits closer to the ground: whether the liquid in a particular vial is actually the molecule on its label, at the dose on its label, and nothing else. Lately the answer to that second question has been getting its own headlines, and they aren't reassuring.

What the testing keeps finding

In an AJMC interview published October 5, Catherine Varney, an obesity-medicine physician at UVA Health, laid out the problem in plain numbers. A finished medicine is expected to run 99 to 100 percent pure. Analyses of gray-market peptides, she said, have turned up products holding only 5 to 75 percent of the dose printed on the label, and some carrying contaminants, arsenic among them, at up to ten times the level considered acceptable. She made one point that's easy to skip past: most of these are injected, not swallowed, so a contaminant skips the gut and goes straight in.

She isn't an outlier. Reporting this fall has described independent lab tests of products sold as research peptides that came back with incorrect dosages, missing active ingredient, or simple contamination. A JAMA account of black-market material labeled as retatrutide, the experimental weight-loss compound, documented hospitalizations, liver injury, and in one case an esophageal rupture; testing of the seized products found some with the wrong amount of drug and some with an entirely different ingredient. The pattern is consistent enough to be the story.

Why this is a different question

It's worth being precise about what these findings do and don't touch. A clean Phase 2 trial of a compound tells you something about the molecule, studied under controlled conditions, made to pharmaceutical specification. It tells you nothing about the unbranded vial a stranger shipped from an overseas manufacturer with no one checking the contents on the way. The trial result and the vial are not the same evidence, and a strong result for the first can quietly get borrowed as confidence in the second.

That borrowing is the trap. "The research looks promising" is a statement about a substance under ideal conditions. "This is safe to use" is a statement about a specific product, and the second doesn't follow from the first when no one has verified that the product is even what it claims to be. Varney's framing is that quality assurance, the entire job a regulator and a manufacturer normally do, falls instead on the unregulated seller. Which is to say it mostly doesn't get done.

The verification gap

The honest independent check exists, but it's rare and it's expensive. Varney described a patient community that pools money to send samples to third-party labs and reads the certificates together, and noted what that requires: a level of health literacy, coordination, and cash most people don't have, to do by hand the one thing a functioning supply chain is supposed to do for free. A certificate of analysis from the seller isn't that. It's a document from the party with the least reason to fail the product.

None of this is an argument about any compound's biology, and it isn't a prescription for what to do. It's a narrower and more durable point. When a thing is sold outside the system that tests it, the gap between the label and the contents isn't an edge case to rule out. It's the base rate, and the testing we have keeps confirming it. The molecule can be real, the research can be real, and the vial in your hand can still be a stranger. Those stay three separate facts no matter how good the first two look.

---

This post is educational and general in nature. It is not medical advice. For guidance about your own health, talk to a qualified clinician.